vimarsana.com
Home
Live Updates
FDA grants Priority Review to Roche's inavolisib for advance
FDA grants Priority Review to Roche's inavolisib for advance
FDA grants Priority Review to Roche's inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
Priority Review recognises the best-in-class potential of the inavolisib-based regimen for patients in urgent need of new treatment options1,2Additional analyses of INAVO120 will be presented in an...
Related Keywords
Japan ,
San Antonio ,
Texas ,
United States ,
Switzerland ,
American ,
America ,
Kirti Pandey ,
Loren Kalm ,
Karsten Kleine ,
Sabine Borngr ,
Simon Goldsborough ,
Birgit Masjost ,
Levi Garraway ,
Bruno Eschli ,
Rebekka Schnell ,
Sileia Urech ,
Nathalie Altermatt ,
Yvette Petillon ,
European Medicines Agency ,
National Cancer Institute ,
Drug Administration ,
Genentech ,
Roche Group ,
Wales Cancer Network ,
Head Of Global Product Development ,
Ends Result Program ,
American Society Of Clinical Oncology Annual Meeting ,
Priority Review ,
Clinical Oncology Annual ,
New Drug Application ,
Chief Medical Officer ,
Global Product ,
Prescription Drug User Fee Act ,
European Medicines ,
Therapy Designation ,
Clinical Oncology Annual Meeting ,
Dow Jones Sustainability Indices ,
Chugai Pharmaceutical ,
Systematic Review ,
Diagnostic Workup ,
Metastatic Breast ,
Intj Breast ,
San Antonio Breast Cancer Symposium ,
Breakthrough Therapy Approvals ,
Study Evaluating ,
Patients With ,
Hormone Receptor Positive ,
Locally Advanced ,
Metastatic Breast Cancer ,
Participants With ,
Metastatic Breast Cancer Post ,
Endocrine Combination Therapy ,
Combination With Phesgo Versus Placebo ,
Combination With Phesgo ,
Positive Locally Advanced ,
Cancer Institute ,
Ends Result ,
Cancer Stat Facts ,
Female Breast Cancer Subtypes ,
Williston Park ,
Adv Med ,